NEW YORK – December 6, 2022 – Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced their partnership with The Massachusetts Medical Society (“MMS”), a statewide professional association for physicians and medical students, supporting more than 25,000 members.

This collaboration between Click and the MMS will support medical students and physician scientists by fostering innovation in medical practice, research, and education. Beginning this year, Click will sponsor the MMS Information Technology in Medicine Award, which is given annually to a medical student and to a resident, or fellow that uses technology to assist physicians in the practice of medicine, in teaching medicine, or in the pursuit of clinical research.

Click’s specialized expertise in developing novel digital interventions in combination with MMS’s leading voice in health care policy, public health, and clinical medical education will promote collaborations that will shape the future of digital therapeutics (DTx) integration into the practice of care.

“We at Click are thrilled to partner with the MMS as we share a common desire to advance the practice of medicine and democratize access to high-quality care. We are not developing prescription digital therapeutics to solely create a new category of medicine. Rather, we find that responsibly leveraging technology is vital for our systems of care to overcome the pain points experienced by our patients and fellow physicians.” said Shaheen Lakhan, MD, PhD, FAAN, Chief Medical Officer (CMO), Click Therapeutics.

For more information on the partnership and the IT awards see massmed.org/cit_award/.

The Massachusetts Medical Society (MMS) is the statewide professional association for physicians and medical students, supporting 25,000 members. We are dedicated to educating and advocating for the physicians of Massachusetts and patients locally and nationally. A leadership voice in health care, the MMS contributes physician and patient perspectives to influence health-related legislation at the state and federal levels, works in support of public health, provides expert advice on physician practice management, and addresses issues of physician well-being. Under the auspices of the NEJM Group, the MMS extends our mission globally by advancing medical knowledge from research to patient care through the New England Journal of Medicine, NEJM Catalyst, NEJM Evidence and the NEJM Journal Watch family of specialty publications, and through our education products for health care professionals: NEJM Knowledge+, NEJM Resident 360, and our accredited and comprehensive continuing medical education programs. For more information about the MMS visit: www.massmed.org.

Click Therapeutics, Inc. develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. We are expanding the possibilities of medicine with Digital Therapeutics™ that combine clinical science with the power of software to create a new way to treat disease.  

Operating at the intersection of biology and technology, we use a proprietary platform-based approach to therapeutic development that leverages patient-centric design principles and innovative AI-based technologies to deliver a unique combination of engagement and clinical outcomes, consistently. Digital therapeutics on Click’s platform are regulated, clinically validated prescription mobile applications that can address diverse areas of therapeutic need, including indications in psychiatry, neurology, oncology, immunology, and cardiometabolic diseases. 

Click Therapeutics, in collaboration with Otsuka, developed the first prescription digital therapeutic authorized by the FDA for the adjunctive treatment of major depressive disorder symptoms, Rejoyn™. In October 2024, in response to FDA guidance on prescription drug use-related software (PDURS), we launched Click SE™ to extend our digital therapeutics platform and expertise to the development of software-enhanced drug™ therapies that combine software with pharmacotherapy to offer added clinically meaningful benefit to patients.

Our commitment to advancing digital medicine means we continually improve our platform technologies, ensuring we stay at the forefront of cognitive, behavioral, and neuromodulatory therapeutic innovation, to achieve the best possible outcomes for patients. Our diverse team of innovators—spanning clinicians, researchers, technologists, designers and more—works together to create cutting-edge digital therapeutics, united in the mission to transform patient care. For more information, visit www.clicktherapeutics.com and connect with us on LinkedIn.